Cell & Gene State of the Industry Briefing

ARM’s hybrid 2023 Cell & Gene State of the Industry Briefing will attract over 400+ key stakeholders in the field. This event includes ARM’s annual yearly update on the sector’s progress followed by two panel sessions featuring top CEOs and executives highlighting future inflection points for cell and gene therapies in the coming year.

Who Attends?

Over 400 of the cell and gene therapy field’s top stakeholders including company founders, C-level business executives, investors, media, patient advocates and academic leaders interested in learning more on the sector’s recent advances and outlook for the industry in the coming year.